Dexcom G6 device receives CE Mark for treating people with diabetes

The Dexcom G6 continuous glucose monitoring (CGM) system has received a CE Mark for treating people with diabetes aged two and above in the UK.
The CE Mark means the CGM meets the essential requirements of the Medical Device Directive MDD, relating to laws within the European Union.
The technology, made by Dexcom, will be made available in the UK and Ireland this month, followed by a European introduction later this year.
A non-invasive device, the G6 eliminates the need for finger pricking, a hindrance for younger children, as well as other people with diabetes.
Professor Nick Oliver, who is a consultant in diabetes and endocrinology at Imperial College London, said: “For many years, fingerstick blood glucose testing has been a critical component of diabetes self-management.
“With Dexcom G6, people with diabetes now have the freedom to live without routine fingersticks and can rely on their CGM data to make treatment decisions, enabling more personalised and effective self-management.”
The G6 is a stand-alone CGM system for people who inject multiple times a day. It can also be used by those who rely on insulin pump therapy.
The sensor on the device is disposable and should be changed every 10 days. It is easily inserted under the skin to measure blood sugar levels.
Alarms alert the user – or in the case of children, their parents – to when glucose levels are at dangerous levels when they are asleep. An app that works alongside the technology allows the user to share their data with their healthcare professionals.
Dexcom’s general manager John Lister said: “The Dexcom G6 represents the future of diabetes management. Not only does the product eliminate the need for fingersticks, but it also maintains the performance, connectivity and accuracy that the diabetes community has come to expect from Dexcom CGM.”